TY - JOUR
T1 - Improvement of survival in Korean breast cancer patients over a 14-year period
T2 - A largescale single-center study
AU - Kim, Hakyoung
AU - Lee, Sae Byul
AU - Kim, Jisun
AU - Chung, Il Yong
AU - Kim, Hee Jeong
AU - Ko, Beom Seok
AU - Lee, Jong Won
AU - Son, Byung Ho
AU - Ahn, Sei Hyun
N1 - Publisher Copyright:
© 2022 Kim et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
PY - 2022/3
Y1 - 2022/3
N2 - Purpose The aim of this study was to evaluate the chronological changes over 14 years in the survival of Korean patients with breast cancer. We also sought to investigate the factors that may have influenced the changes in survival rate. Materials and methods We retrospectively analyzed 17,776 breast cancer patients who were treated at Asan Medical Center between January 2000 and December 2013. Patient information was collected from the Asan database, including age at diagnosis, clinical manifestation, pathology report, types of treatment and modality, types of recurrence, and follow-up period. We classified the patients into two cohorts according to the year of their surgery (P1: 2000-2007 and P2: 2008-2013) and compared survival and recurrence between both cohorts. Results We observed that patients treated more recently had better survival outcomes. The 5-year breast cancer-specific survival increased from 94.0% in P1 to 96.6% in P2 (p<0.001), and the 5-year disease-free survival increased from 87.9% in P1 to 91.2% in P2 (p<0.001). When analyzed by type of recurrence, distant metastasis-free survival increased to a significant degree. In subgroup analysis by the subtypes of breast cancer, the survival rates improved in all of the subtypes except triple negative breast cancer, and the improvement was more prominent in subtypes with overexpressed human epidermal growth factor receptor 2. Conclusion This study showed improvement in breast cancer survival over the succeeding years, which is consistent with the advancement in systemic therapy.
AB - Purpose The aim of this study was to evaluate the chronological changes over 14 years in the survival of Korean patients with breast cancer. We also sought to investigate the factors that may have influenced the changes in survival rate. Materials and methods We retrospectively analyzed 17,776 breast cancer patients who were treated at Asan Medical Center between January 2000 and December 2013. Patient information was collected from the Asan database, including age at diagnosis, clinical manifestation, pathology report, types of treatment and modality, types of recurrence, and follow-up period. We classified the patients into two cohorts according to the year of their surgery (P1: 2000-2007 and P2: 2008-2013) and compared survival and recurrence between both cohorts. Results We observed that patients treated more recently had better survival outcomes. The 5-year breast cancer-specific survival increased from 94.0% in P1 to 96.6% in P2 (p<0.001), and the 5-year disease-free survival increased from 87.9% in P1 to 91.2% in P2 (p<0.001). When analyzed by type of recurrence, distant metastasis-free survival increased to a significant degree. In subgroup analysis by the subtypes of breast cancer, the survival rates improved in all of the subtypes except triple negative breast cancer, and the improvement was more prominent in subtypes with overexpressed human epidermal growth factor receptor 2. Conclusion This study showed improvement in breast cancer survival over the succeeding years, which is consistent with the advancement in systemic therapy.
UR - http://www.scopus.com/inward/record.url?scp=85126619849&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0265533
DO - 10.1371/journal.pone.0265533
M3 - Article
C2 - 35294484
AN - SCOPUS:85126619849
SN - 1932-6203
VL - 17
JO - PLoS ONE
JF - PLoS ONE
IS - 3 March
M1 - e0265533
ER -
